Oramed agrees to pay $125,000 in legal fees after shareholder suit dismissal
ORMP•Oramed Pharmaceuticals agreed to pay $125,000 in attorneys’ fees and expenses to resolve mooted bylaw claims, without admitting wrongdoing. Delaware’s Court of Chancery dismissed the lawsuit on July 2, 2026.
1. Bylaw claims dismissed
Oramed Pharmaceuticals agreed to pay $125,000 in plaintiff’s attorneys’ fees and expenses to resolve claims over its written-consent bylaw provisions. The Delaware Court of Chancery dismissed the lawsuit on July 2, 2026, retaining jurisdiction solely over counsel’s fee application. The company amended its bylaws on June 28, 2026, rendering the claims moot, and denied that the provisions violated the law.




